NASDAQ:BIOS - BioScrip Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.17 -0.06 (-2.69 %) (As of 05/22/2019 04:00 PM ET)Previous Close$2.23Today's Range$2.09 - $2.2652-Week Range$1.56 - $4.14Volume741,532 shsAverage Volume1.30 million shsMarket Capitalization$279.40 millionP/E RatioN/ADividend YieldN/ABeta0.66 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioScrip, Inc. provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company provides its services at patient's home, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. BioScrip, Inc. offers its solutions through sales and marketing representatives, and payor relationships. The company was incorporated in 1996 and is based in Denver, Colorado. Receive BIOS News and Ratings via Email Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:BIOS Previous Symbol CUSIP09069N10 CIK1014739 Webhttp://www.bioscrip.com/ Phone720-697-5200Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$708.90 million Price / Sales0.39 Cash FlowN/A Price / Cash FlowN/A Book Value($1.21) per share Price / Book-1.79Profitability EPS (Most Recent Fiscal Year)($0.49) Net Income$-51,690,000.00 Net Margins-6.81% Return on EquityN/A Return on Assets-8.41%Miscellaneous Employees2,043 Outstanding Shares128,758,000Market Cap$279.40 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable BioScrip (NASDAQ:BIOS) Frequently Asked Questions What is BioScrip's stock symbol? BioScrip trades on the NASDAQ under the ticker symbol "BIOS." How were BioScrip's earnings last quarter? BioScrip Inc (NASDAQ:BIOS) announced its quarterly earnings data on Thursday, May, 2nd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The business earned $178.96 million during the quarter, compared to the consensus estimate of $179.23 million. BioScrip's revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.12) earnings per share. View BioScrip's Earnings History. When is BioScrip's next earnings date? BioScrip is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for BioScrip. What price target have analysts set for BIOS? 4 brokerages have issued twelve-month price objectives for BioScrip's stock. Their forecasts range from $2.51 to $10.00. On average, they anticipate BioScrip's stock price to reach $5.0025 in the next twelve months. This suggests a possible upside of 130.5% from the stock's current price. View Analyst Price Targets for BioScrip. What is the consensus analysts' recommendation for BioScrip? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip. What are Wall Street analysts saying about BioScrip stock? Here are some recent quotes from research analysts about BioScrip stock: 1. Barrington Research analysts commented, "We think they should have held one given that management is currently engaged in selling BIOS investors on the benefits of the pending Option Care transaction." (5/3/2019) 2. According to Zacks Investment Research, "In the last-reported quarter, BioScrip's revenues getting affected by the impact of higher core product mix, including the impact of contract changes with UnitedHealthcare worries us. However, we are encouraged by the company’s progress in the third quarter, courtesy of its new multi-faceted CORE plan to improve its financial position. The company also expects to earn core revenues at Home Solutions and witness continued core growth. The company also took certain rigorous steps to revitalize its sales force in the reported quarter. These developments should further drive business growth in 2018. Overall, BioScrip has outperformed its industry in the past six months." (1/3/2019) Has BioScrip been receiving favorable news coverage? News stories about BIOS stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BioScrip earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. Are investors shorting BioScrip? BioScrip saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 10,563,181 shares, an increase of 19.7% from the April 15th total of 8,822,312 shares. Based on an average daily trading volume, of 1,676,330 shares, the days-to-cover ratio is currently 6.3 days. Approximately 8.3% of the company's shares are sold short. View BioScrip's Current Options Chain. Who are some of BioScrip's key competitors? Some companies that are related to BioScrip include Chemed (CHE), LHC Group (LHCG), Amedisys (AMED), Addus Homecare (ADUS), Civitas Solutions (CIVI) and New York Health Care (BBAL). What other stocks do shareholders of BioScrip own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioScrip investors own include Abraxas Petroleum (AXAS), Northern Oil & Gas (NOG), Advanced Micro Devices (AMD), Acasti Pharma (ACST), Novavax (NVAX), Opko Health (OPK), Seanergy Maritime (SHIP), JPMorgan Chase & Co. (JPM), BioDelivery Sciences International (BDSI) and Cisco Systems (CSCO). Who are BioScrip's key executives? BioScrip's management team includes the folowing people: Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 54)Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)Ms. Harriet Booker, Sr. VP & COO (Age 52)Mr. John McMahon, VP, Controller & Chief Accounting Officer (Age 54)Mr. Vito Ponzio Jr., Chief Admin. Officer & Sr. VP (Age 64) Who are BioScrip's major shareholders? BioScrip's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (10.57%), BlackRock Inc. (6.96%), Gabelli Funds LLC (5.28%), FMR LLC (3.01%), Rothschild & Co. Asset Management US Inc. (2.96%) and Dimensional Fund Advisors LP (2.23%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, Michael G Bronfein and Stephen Deitsch. View Institutional Ownership Trends for BioScrip. Which institutional investors are selling BioScrip stock? BIOS stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, BlackRock Inc., JPMorgan Chase & Co., Gabelli Funds LLC, Wells Fargo & Company MN, Morgan Stanley, FMR LLC and Diamond Hill Capital Management Inc.. View Insider Buying and Selling for BioScrip. Which institutional investors are buying BioScrip stock? BIOS stock was purchased by a variety of institutional investors in the last quarter, including Rothschild & Co. Asset Management US Inc., Essex Investment Management Co. LLC, SEI Investments Co, Dimensional Fund Advisors LP, Stephens Inc. AR, Raymond James & Associates, Prescott Group Capital Management L.L.C. and Geode Capital Management LLC. Company insiders that have bought BioScrip stock in the last two years include Daniel E Greenleaf and Stephen Deitsch. View Insider Buying and Selling for BioScrip. How do I buy shares of BioScrip? Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioScrip's stock price today? One share of BIOS stock can currently be purchased for approximately $2.17. How big of a company is BioScrip? BioScrip has a market capitalization of $279.40 million and generates $708.90 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. BioScrip employs 2,043 workers across the globe. What is BioScrip's official website? The official website for BioScrip is http://www.bioscrip.com/. How can I contact BioScrip? BioScrip's mailing address is 1600 BROADWAY SUITE 700, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected] MarketBeat Community Rating for BioScrip (NASDAQ BIOS)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 281 (Vote Outperform)Underperform Votes: 217 (Vote Underperform)Total Votes: 498MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Treasury Bonds Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.